Lupus Low Disease Activity State (LLDAS) study is an international, multi-centre prospective study, developed by the Asia Pacific Lupus Collaboration (APLC) to investigate whether the attainment of LLDAS is associated with improved outcomes in patients with Systemic Lupus Erythematosus (SLE).
SLE, or lupus, is the archetypal multisystem autoimmune disease, with an estimated incidence of 5-50 cases per 100,000 people. Patients with SLE, usually young women, suffer a marked loss of life expectancy, and severe morbidity, due to a heterogeneous range of clinical manifestations caused by autoimmune-mediated inflammation of multiple organs. The most severe manifestations of SLE are the accrual of irreversible organ damage, especially renal and central nervous system (CNS) involvement. As there is no effective targeted monotherapy for SLE, patients also suffer severe toxicity from the use of glucocorticoids and broad-spectrum immunosuppressive therapies. Despite combination therapy with current drugs, many studies show that the majority of patients suffer inadequate disease control and inexorably accrue permanent organ damage over time.
The diversity of clinical features of active SLE has made quantification of disease activity problematic. Although there are a number of published systems in use to measure SLE disease activity, there are widely acknowledged problems with these instruments. Published definitions of remission are so stringent that they are met by less than 5% of patients. This lead to the realisation that rather than lupus remission, a lupus low disease activity state target may be more feasible, and that patients with low disease activity are more homogeneous than patients with active disease. Thus, the development of a definition of lupus low disease activity, which is feasible and has face validity, escapes the complexity of attempts to quantify heterogeneous states of active disease.
In this study, the investigators will prospectively collect longitudinal data on consecutive SLE patients at each centre to evaluate the LLDAS definition. Protection from organ damage accrual as the primary endpoint.

开始日期2013-09-01

申办/合作机构

Monash University

[+11]

0 项与 Teaching Hospital Kandy 相关的专利（医药）

登录后查看更多信息

项与 Teaching Hospital Kandy 相关的文献（医药）

2022·Open Journal of Obstetrics and Gynecology

A comparison of amniotic fluid index versus single deepest vertical pocket measurement at term as a predictor of adverse perinatal outcome

作者: Gunasingha, Hasitha ; Hemapriya, Sardha ; Mendis, Sachini

Introduction: Oligohydramnios is an important sign of fetal jeopardy and amniotic fluid index (AFI) and single deepest vertical pocket (SDVP) have been used to detect it. Objective: To compare AFI vs. SDVP at term as a predictor of adverse perinatal outcomes. Methods: A prospective observational study was conducted in Teaching Hospital Kandy, Sri Lanka for eight months from July 2015 to March 2016. 448 Singleton pregnancies admitted after 37 completed weeks were included. AFI ≤ 5 cm and SDVP < 2 cm were the exposure variables, which were related to outcome variables. Results: Mean AFI was 11.35 cm (SD = 5.15) and Mean SDVP was 4.07 cm (SD = 1.88). AFI and SDVP values showed a significant pos. correlation (r = 0.954; p < 0.001). A significant percentage with low AFI needed induction of labour (RR 2.14, 95% CI 1.85 - 2.49). Low AFI was also a significant risk factor for not having an uneventful birth outcome (RR 2.682, 95% CI 1.082 - 6.642). Low SDVP was a significant risk factor for induction of labour (RR 1.83, 95% CI 1.434 - 2.334), operative delivery (RR 1.714, 95% CI 1.292 - 2.280), meconium- stained liquor (RR 2.67, 95% CI 1.342 - 5.308), and Apgar < 7 (RR 17.74, 95% CI 7.96 - 40.924). SDVP had better predictability than AFI for adverse perinatal outcomes. Conclusion: AFI better predicted oligohydramnios and subsequent labour induction than SDVP. Low SDVP was a risk factor for adverse perinatal outcomes (such as induction of labour, meconium-stained liquor, operative delivery, 5-min Apgar less < 7, admission to special care baby units or perinatal deaths). In predicting adverse perinatal events, a higher potential was noted in SDVP method than AFI method. To determine the most predictive cut-off values of SDVP and AFI for each perinatal outcome, an in-depth exptl. anal. is required in future research.

2019·Radiology and Oncology

A multi-institutional analysis of diffuse large B-cell lymphoma (DLBCL) treated with consolidative radiotherapy and the impact of cell-of-origin on outcomes

作者: Rajasooriyar, Chrishanthi ; Tey, Jeremy ; Wong, Lea Choung ; Poon, Michelle ; Nandini, Rao ; Tham, Ivan ; Vellayappan, Balamurugan

A review. We aim to review the outcome, as well as determine the impact of cell-of-origin, on patients undergoing consolidative RT. Results : Seventy-four patients were included in this anal. The median follow up was 3 years (0.7-16 years). Fifty-eight percent of patients had stage I-II disease, and 61% received at least 6 cycles of chemotherapy. Cell-of-origin was discernible in 60% of patients, and approx. half were classified as Germinal center origin. The 5-yr overall survival (OS) of this group was excellent at 92% (median survival not reached). The 5-yr DFS was 73% (95% CI 57-83%). Seven percent (n = 5) of patients experienced local recurrence at a median time of 6 mo. Failure to achieve complete response post RT and/or initial bulky disease are significant predictors of inferior DFS. There was no association between cell-of-origin and DFS or OS. Conclusions : The outcome of patients who received radiotherapy as consolidation is excellent. Patients who fail to achieve complete response after radiotherapy had poorer outcomes. Despite using radiotherapy, presence of bulky disease remains a significant predictor of disease recurrence. We did not find any association of poorer outcomes, with regards to cell-of-origin, in the use of consolidative RT.

2018·Journal of Obstetrics and Gynaecology Research

Randomized control trial comparing effectiveness of weekly versus daily antenatal oral iron supplementation in preventing anemia during pregnancy

作者: Goonewardene, Indra Malik R. ; Senadheera, Diluk I.

Aim : This study was conducted to determine whether weekly antenatal oral iron and folate supplementation is an effective alternative to a daily regimen in non-anemic pregnant women to prevent anemia and iron deficiency during the third trimester. Methods : From Dec. 2014 to Apr. 2015, non-anemic pregnant women (n = 292) who presented to the Academic Obstetric Unit, Teaching Hospital Mahamodera Galle, Sri Lanka, at 14-22 wk gestation and who had been treated with mebendazole 100 mg twice daily for three days were randomly allocated to receive 120 mg elemental iron, 3 mg folic acid and 100 mg vitamin C weekly (n = 149) or 60 mg elemental iron, 1 mg folic acid and 100 mg vitamin C daily (n = 143). Side effects were assessed at four weekly intervals and Hb concentration (Hb), hematocrit and serum ferritin (SF) were measured at 32-36 wk gestation. Results : Only 106 participants in each group completed the study. There were no significant differences between the groups in mean duration of supplementation; presupplementation and post-supplementation mean Hb, hematocrit or SF levels; risk of developing anemia, ID or high Hb levels by an intension to treat anal.; and in those who completed the trial. Significantly greater side effects occurred in the daily compared to the weekly supplementation group. Conclusion : In non-anemic pregnant women, a weekly regimen is an effective alternative to a daily regimen for antenatal oral iron and folate supplementation for preventing anemia and iron deficiency during the third trimester.

项与 Teaching Hospital Kandy 相关的新闻（医药）

2021-08-19

·GlobeNewswire

Technology Leader Pushpay Announces New Executive Leadership, Promotes Kevin Kuck to Chief Operations Officer

REDMOND, Wash., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Pushpay (NZSX:PPH, ASX:PPH, 'Pushpay' or 'the Company'), the leading payments and engagement solutions provider for the faith-based, non-profit, and education sectors, today announces the appointment of Kevin Kuck as Chief Operations Officer. Kuck previously served as the Senior Vice President of Operations. “Kevin has been a pivotal part of Pushpay’s growth and corporate development journey over the years,” said Molly Matthews, Pushpay’s CEO. “He brings invaluable technical knowledge to our organization, and as we look to the future of our company, his thoughtful leadership approach will be vital as we continue to build world-class teams and solutions for our customers.” Kuck has spent nearly seven years at Pushpay, and his expertise on organizational design and process improvement has helped enable the Company to quickly scale amidst years of rapid growth. He was also an integral part of the success of the recent Church Community Builder acquisition, where he guided the Company’s IT and Operations teams through the business integration process. His leadership has also helped ensure the longevity of Pushpay’s systems and tools—which enable the Company and its employees to serve its customers well. Prior to his time at Pushpay, Kuck held a variety of sales, recruitment and leadership roles across the U.S. and New Zealand, including roles with Fairfax Media, Catch Software, and The Teaching Company. He came to Pushpay in 2014 as an Operations and Insight Manager and was promoted to Vice President of Operations in 2015. In 2018 Kevin took on the role of Senior Vice President of Operations, which was his last position before the promotion to Chief Operations Officer. In addition to this executive change, Pushpay’s Chief Financial Officer Shane Sampson has announced his resignation, effective October 2021. Shane joined Pushpay as CFO in October 2015 and during his tenure he played a pivotal role in capital fund raising and helped lead the Company through double digit growth. Pushpay has begun an executive search to appoint a CFO who will be based in the Company’s Redmond, Washington, U.S. office and will advise the market in due course. To learn more or to apply, visit . To learn more about Pushpay, visit . About PushpayPushpay provides a donor management system, including donor tools, finance tools and a custom community app, and a church management system (ChMS) to the faith sector, non-profit organizations and education providers located predominantly in the United States (U.S.) and other jurisdictions. Our leading solutions simplify engagement, payments and administration, enabling our Customers to increase participation and build stronger relationships with their communities. Church Community Builder is an affiliate of Pushpay Holdings Limited and provides a Software as a Service (SaaS) church management system predominantly in the U.S. and other jurisdictions. Church Community Builder provides a platform that churches use to connect and communicate with their community members, record member service history, track online giving and perform a range of administrative functions. Combined, Pushpay and Church Community Builder deliver a best-in-class, fully integrated ChMS, custom community app and giving solution for customers in the US faith sector. Media ContactBrittany JohnsonUproar PR for Pushpaybjohnson@uproarpr.com312-878-4575 x246 A photo accompanying this announcement is available at:

高管变更并购